Drug Approval | September 25, 2023
Strides receives USFDA approval for Icosapent Ethyl Capsules
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD)
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD)
Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa
The products will be manufactured at the company's facility in Bengaluru
The products will be manufactured at the company's facility in Bengaluru
The approval bolsters the company's Mycophenolate Mofetil portfolio
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
DKSH has further fortified its strategic partnership with Biolin Scientific, a globally recognized pioneer in surface science instrumentation, across nine key markets in the APAC region
Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
